Findings from the latest analysis of the Partner study of Edwards Lifesciences' Sapien transcatheter aortic valve replacement suggest the procedure may beat traditional aortic valve replacement surgery only when conducted transfemorally.

Edwards Lifesciences' Sapien TAVI

Newly unveiled results from Edwards Lifesciences (NYSE:EW) transcatheter aortic valve studies showed mixed results for its Sapien TAVI system when compared with surgical aortic valve replacement.

Transfemoral TAVI treatment was the standout in terms of cost-effectiveness and quality-of-life-years following treatment, but TAVI treatment via the transapical approach looked less favorable than open-heart aortic valve surgery.

The study was the 1st attempt to direct attempt to assess costs of TAVI procedures relative to surgery in patients who are at high risk but still candidates for surgery, researchers noted.